Main Inclusion Criteria:

        - Male or female patients, 18 years of age or older who sign the informed consent document,
        are willing and able to comply with the study protocol and have:

        Part 1 (Dose Escalation):

        - Histologically or cytologically proven advanced solid tumour for which there is no
        curative therapy and has progressed on Standard of Care (SOC) treatment or is intolerant to
        or has no available SOC or SOC unacceptable.

        Part 2 (Dose Expansion):

        - Histologically or cytologically proven advanced NSCLC whose tumours are KRAS-mutated and
        where the disease has progressed after a chemotherapy and immunotherapy regimen (at least
        two prior lines of standard therapy), advanced TNBC where the disease has progressed after
        having received anthracyclines and taxanes (at least two prior lines of standard therapy)
        and advanced CRC whose tumours are RAS mutated and where the disease has progressed after
        at least two prior lines of standard therapy.

        Parts 1 and 2:

          -  Patient must have measurable disease as per RECIST v1.1 criteria

          -  Tumour biopsy (either from the primary tumour or from metastases) during Screening and
             during Treatment should be obtained from the patients, if feasible.

          -  Documented progression on or following the last line of therapy.

          -  ECOG performance status up to 1.

          -  Life expectancy of ≥12 weeks.

          -  Adequate organ function

        Main Exclusion Criteria:

        Parts 1 and 2:

          -  Systemic anti-cancer therapy within 4 weeks prior to study entry.

          -  Radiation therapy within 4 weeks prior to study entry. Localised palliative
             radiotherapy to non-target lesions is allowed.

          -  Non-malignant systemic disease including cerebrovascular accident (CVA), unstable
             angina pectoris, unstable atrial fibrillation, unstable cardiac arrhythmia, myocardial
             infarction in the last 6 months, New York Heart Association (NYHA) Class III or IV
             heart failure, coagulation abnormalities and clinically significant pulmonary
             compromise, particularly a requirement for supplemental oxygen use to maintain
             adequate oxygenation in the previous 6 months.

          -  Patients with a history of congenital or acquired immunodeficiency syndrome, or
             currently receiving immunosuppressive therapy >10 mg prednisolone or equivalent.
             Patients receiving inhaled or topical corticosteroids are eligible.

          -  Patients with symptomatic or unstable central nervous system (CNS) primary tumour or
             metastases and/or carcinomatous meningitis. Patients with documented treated CNS
             metastases stable for at least 4 weeks may be enrolled at the discretion of the
             Investigator.

          -  Patients with need of therapeutic anticoagulation.